CERC News and Press, Cerecor Inc. From 08/26/21

Name change underscores the Company’s transition to developing innovative targeted therapies in immunology, immuno-oncology, and rare genetic diseases Robust pipeline of six product candidates advancing in development with eight ongoing clinical programs Four therapies with...

Announced positive results for low-dose cohort of CERC-002 (1.0 mg/kg) in moderate-to-severe Crohn's disease patients who had previously failed three or more lines of biologic therapies, including anti-TNF alpha treatments Announced plans to explore CERC-002 in patients with m...

Cerecor (NASDAQ:CERC) completed its second drawdown of $10M under its previously announced $35M debt financing agreement with Horizon Technology Finance (NASDAQ:HRZN). The biopharmaceutical company said the second tranche was made available in connection with positive results from its ph...

ROCKVILLE, Md. and CHESTERBROOK, Pa., Aug. 02, 2021 (GLOBE NEWSWIRE) -- Cerecor Inc. (NASDAQ: CERC), a biopharmaceutical company focused on becoming a leader in the development and commercialization of treatments for immunologic, immuno-oncologic and rare genetic disorders, today announced ...

Cerecor  (CERC) shares surge over 23% after posting positive initial results from a Phase 1b proof-of-concept study evaluating CERC-002 in adult patients with moderate to severe Crohn's disease ((CD)).The trial is designed to initially evaluate two doses of CERC-002 ȁ...

Positive results for low-dose cohort of CERC-002 (1.0 mg/kg) in moderate to severe Crohn's disease patients who had previously failed three or more lines of biologic therapies, including anti-TNF alpha treatments Mean reduction in LIGHT levels of approximately 80% compared to ...

Cerecor (CERC) announces that it has entered into an exclusive license agreement with Sanford Burnham Prebys for the worldwide development and commercialization of an immune checkpoint program. Under the terms of the agreement, Sanford Burnham Prebys will receive an u...

ROCKVILLE, Md., June 23, 2021 (GLOBE NEWSWIRE) -- Cerecor Inc. (NASDAQ: CERC), a biopharmaceutical company focused on becoming a leader in the development and commercialization of treatments for immunology, immuno-oncology and rare genetic disorders, today announced that it has entered into...

Cerecor shares rise ([[CERC]] +13.8%) after announcing that it has entered into a debt financing agreement led by Horizon Technology Finance to provide up to $35M in term loans.The company said that the financing provides flexibility and extends runway through multiple clinical catalysts...

An initial tranche of $20 million drawn at the loan closing Funds ongoing clinical development of key investigational product candidates Financing provides flexibility and extends runway through multiple clinical catalysts expected in 2021 ROCKVILLE, Md. and ...